Prospective Grant of Start-Up Exclusive Patent License Agreement: Treatment of Breast Cancer, Prostate Cancer, Ewing Sarcoma, and Thymoma, 15136-15137 [2014-05867]
Download as PDF
<![CDATA[
emcdonald on DSK67QTVN1PROD with NOTICES
15136
Federal Register / Vol. 79, No. 52 / Tuesday, March 18, 2014 / Notices
Service at (800) 877–8339. Requests
should be made at least five business
days in advance of the event.
The preliminary agenda and draft TRs
should be posted on the NTP Web site
(https://ntp.niehs.nih.gov/go/36051) by
April 10, 2014. Additional information
will be posted when available or may be
requested in hardcopy, see FOR FURTHER
INFORMATION CONTACT. Following the
meeting, a report of the peer review will
be prepared and made available on the
NTP Web site. Registered attendees are
encouraged to access the meeting Web
page to stay abreast of the most current
information.
Request for Comments: The NTP
invites written and oral public
comments on the draft TRs. The
deadline for submission of written
comments is May 8, 2014, to enable
review by the peer-review panel and
NTP staff prior to the meeting.
Registration to provide oral comments is
by May 15, 2014, at https://
ntp.niehs.nih.gov/go/36051. Public
comments and any other
correspondence on the draft TRs should
be sent to the FOR FURTHER INFORMATION
CONTACT. Persons submitting written
comments should include their name,
affiliation, mailing address, phone,
email, and sponsoring organization (if
any) with the document. Written
comments received in response to this
notice will be posted on the NTP Web
site, and the submitter will be identified
by name, affiliation, and/or sponsoring
organization.
Public comment at this meeting is
welcome, with time set aside for the
presentation of oral comments on the
draft TRs. In addition to in-person oral
comments at the NIEHS, public
comments can be presented by
teleconference line. There will be 50
lines for this call; availability is on a
first-come, first-served basis. The lines
will be open from 8:30 a.m. until
approximately 5:00 p.m. EDT on May
22, 2014, although oral comments will
be received only during the formal
public comment periods indicated on
the preliminary agenda. The access
number for the teleconference line will
be provided to registrants by email prior
to the meeting. Each organization is
allowed one time slot per draft TR. At
least 7 minutes will be allotted to each
time slot, and if time permits, may be
extended to 10 minutes at the discretion
of the chair.
Persons wishing to make an oral
presentation are asked to register online
at https://ntp.niehs.nih.gov/go/36051 by
May 15, 2014, indicate whether they
will present comments in-person or via
the teleconference line, and indicate the
TR(s) on which they plan to comment.
VerDate Mar<15>2010
18:34 Mar 17, 2014
Jkt 232001
If possible, oral public commenters
should send a copy of their slides and/
or statement or talking points at that
time. Written statements can
supplement and may expand the oral
presentation. Registration for in-person
oral comments will also be available at
the meeting, although time allowed for
presentation by on-site registrants may
be less than that for registered speakers
and will be determined by the number
of speakers who register on-site.
Background Information on NTP PeerReview Panels: NTP panels are
technical, scientific advisory bodies
established on an ‘‘as needed’’ basis to
provide independent scientific peer
review and advise the NTP on agents of
public health concern, new/revised
toxicological test methods, or other
issues. These panels help ensure
transparent, unbiased, and scientifically
rigorous input to the program for its use
in making credible decisions about
human hazard, setting research and
testing priorities, and providing
information to regulatory agencies about
alternative methods for toxicity
screening. The NTP welcomes
nominations of scientific experts for
upcoming panels. Scientists interested
in serving on an NTP panel should
provide current curriculum vitae to the
FOR FURTHER INFORMATION CONTACT. The
authority for NTP panels is provided by
42 U.S.C. 217a; section 222 of the Public
Health Service (PHS) Act, as amended.
The panel is governed by the Federal
Advisory Committee Act, as amended (5
U.S.C. Appendix 2), which sets forth
standards for the formation and use of
advisory committees.
Dated: March 10, 2014.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2014–05895 Filed 3–17–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Patent License Agreement:
Treatment of Breast Cancer, Prostate
Cancer, Ewing Sarcoma, and
Thymoma
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Services, is contemplating the grant of a
Start-Up Exclusive Patent License
Agreement to Paris Therapeutics, a
company having a place of business in
Santee, CA, to practice the inventions
embodied in the following patent
applications:
1. U.S. Provisional Patent Application.
No. 61/474,664, filed April 12,
2011; HHS Ref. No.: E–068–2011/0–
US–01; Titled: Human Monoclonal
Antibodies that bind insulin-like
growth factor (IGF) I and II;
Inventors: Dimiter S. Dimitrov
(NCI), Qi Zhao (NCI), and Zhongyu
Zhu (NCI)
2. PCT Application No. PCT/US2012/
033128, filed April 11, 2012; HHS
Ref. No.: E–068–2011/0–PCT–02;
Titled: Human Monoclonal
Antibodies that bind insulin-like
growth factor (IGF) I and II;
Inventors: Dimiter S. Dimitrov
(NCI), Qi Zhao (NCI), and Zhongyu
Zhu (NCI)
3. U.S. Patent Application No. 14/
111,507, filed October 11, 2013;
HHS Ref. No.: E–068–2011/0–US–
03; Titled: Human Monoclonal
Antibodies that bind insulin-like
growth factor (IGF) I and II;
Inventors: Dimiter S. Dimitrov
(NCI), Qi Zhao (NCI), and Zhongyu
Zhu (NCI)
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
territory of the prospective Start-Up
Exclusive Patent License Agreement
may be worldwide, and the field of use
may be limited to ‘‘Antibodies against
Insulin-like Growth Factors IGF–I and
IGF–II for the treatment of breast cancer,
prostate cancer, Ewing sarcoma, and
thymoma.’’
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
2, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Patent License Agreement should be
directed to: Whitney A. Hastings, Ph.D.,
Licensing and Patenting Manager, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 451–
7337; Facsimile: (301) 402–0220; Email:
hastingw@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
E:\FR\FM\18MRN1.SGM
18MRN1
Federal Register / Vol. 79, No. 52 / Tuesday, March 18, 2014 / Notices
World Intellectual Property
Organization.
DEPARTMENT OF HOMELAND
SECURITY
This
technology describes fully human
monoclonal antibodies that have been
affinity maturated against IGF–I and
IGF–II and display extremely high
affinities for IGF–I and IGF–II in the
picoM range. Some of these antibodies
potently inhibited signal transduction
mediated by the IGF–1R interaction
with IGF–I and IGF–II and blocked
phosphorylation of IGF–IR and the
insulin receptor. In addition, they
inhibited migration in the MCF–7 breast
cancer cell line at the picoM range.
Therefore, these antibodies could be
used to prevent binding of IGF–I and/or
IGF–II to its concomitant receptor
IGFIR, consequently, modulating
diseases such as cancer.
The prospective Start-Up Exclusive
Patent License Agreement is being
considered under the small business
initiative launched on October 1, 2011
and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR
part 404. The prospective Start-Up
Exclusive Patent License Agreement
may be granted unless the NIH receives
written evidence and argument, within
fifteen (15) days from the date of this
published notice, that establishes that
the grant of the contemplated Start-Up
Exclusive Patent License Agreement
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive Patent
License Agreement. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
U.S. Customs and Border Protection
SUPPLEMENTARY INFORMATION:
Dated: March 14, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
emcdonald on DSK67QTVN1PROD with NOTICES
[FR Doc. 2014–05867 Filed 3–17–14; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
18:34 Mar 17, 2014
Jkt 232001
[1651–0058]
Agency Information Collection
Activities: Documents Required
Aboard Private Aircraft
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: 30-Day notice and request for
comments; extension of an existing
collection of information.
AGENCY:
U.S. Customs and Border
Protection (CBP) of the Department of
Homeland Security will be submitting
the following information collection
request to the Office of Management and
Budget (OMB) for review and approval
in accordance with the Paperwork
Reduction Act: Documents Required
Aboard Private Aircraft. This is a
proposed extension of an information
collection that was previously
approved. CBP is proposing that this
information collection be extended with
no change to the burden hours. This
document is published to obtain
comments from the public and affected
agencies.
DATES: Written comments should be
received on or before April 17, 2014 to
be assured of consideration.
ADDRESSES: Interested persons are
invited to submit written comments on
this proposed information collection to
the Office of Information and Regulatory
Affairs, Office of Management and
Budget. Comments should be addressed
to the OMB Desk Officer for Customs
and Border Protection, Department of
Homeland Security, and sent via
electronic mail to oira_submission@
omb.eop.gov or faxed to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Tracey Denning,
U.S. Customs and Border Protection,
Regulations and Rulings, Office of
International Trade, 90 K Street NE.,
10th Floor, Washington, DC 20229–
1177, at 202–325–0265.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register (78 FR 77484) on December 23,
2013, allowing for a 60-day comment
period. This notice allows for an
additional 30 days for public comments.
This process is conducted in accordance
with 5 CFR 1320.10.
CBP invites the general public and
other Federal agencies to comment on
proposed and/or continuing information
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
15137
collections pursuant to the Paperwork
Reduction Act of 1995 (Pub. L. 104–13;
44 U.S.C. 3507). The comments should
address: (a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s
estimates of the burden of the collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden including the use
of automated collection techniques or
the use of other forms of information
technology; and (e) the annual costs
burden to respondents or record keepers
from the collection of information (a
total capital/startup costs and
operations and maintenance costs). The
comments that are submitted will be
summarized and included in the CBP
request for Office of Management and
Budget (OMB) approval. All comments
will become a matter of public record.
In this document CBP is soliciting
comments concerning the following
information collection:
Title: Documents Required Aboard
Private Aircraft.
OMB Number: 1651–0058.
Form Number: None.
Abstract: In accordance with 19 CFR
122.27, a commander of a private
aircraft arriving in the U.S. must present
several documents to CBP officers for
inspection. These documents include:
(1) A pilot certificate/license; (2) a
medical certificate; and (3) a certificate
of registration, which is also called a
‘‘pink slip’’ and is a duplicate copy of
the Aircraft Registration Application
(FAA Form AC 8050–1). The
information on these documents is used
by CBP officers as an essential part of
the inspection process for private
aircraft arriving from a foreign country.
These requirements are authorized by
19 U.S.C. 1433, as amended by Public
Law 99–570.
Current Actions: CBP proposes to
extend the expiration date of this
information collection with no change
to the burden hours.
Type of Review: Extension (with
change).
Affected Public: Individuals.
Estimated Number of Respondents:
120,000.
Estimated Number of Annual
Responses: 120,000.
Estimated Time per Response: 1
minute.
Estimated Total Annual Burden
Hours: 1,992.
E:\FR\FM\18MRN1.SGM
18MRN1
]]>Agencies
[Federal Register Volume 79, Number 52 (Tuesday, March 18, 2014)]
[Notices]
[Pages 15136-15137]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05867]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive Patent License Agreement:
Treatment of Breast Cancer, Prostate Cancer, Ewing Sarcoma, and Thymoma
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of a Start-Up Exclusive
Patent License Agreement to Paris Therapeutics, a company having a
place of business in Santee, CA, to practice the inventions embodied in
the following patent applications:
1. U.S. Provisional Patent Application. No. 61/474,664, filed April 12,
2011; HHS Ref. No.: E-068-2011/0-US-01; Titled: Human Monoclonal
Antibodies that bind insulin-like growth factor (IGF) I and II;
Inventors: Dimiter S. Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu
(NCI)
2. PCT Application No. PCT/US2012/033128, filed April 11, 2012; HHS
Ref. No.: E-068-2011/0-PCT-02; Titled: Human Monoclonal Antibodies that
bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S.
Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)
3. U.S. Patent Application No. 14/111,507, filed October 11, 2013; HHS
Ref. No.: E-068-2011/0-US-03; Titled: Human Monoclonal Antibodies that
bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S.
Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)
The patent rights in these inventions have been assigned to the
Government of the United States of America. The territory of the
prospective Start-Up Exclusive Patent License Agreement may be
worldwide, and the field of use may be limited to ``Antibodies against
Insulin-like Growth Factors IGF-I and IGF-II for the treatment of
breast cancer, prostate cancer, Ewing sarcoma, and thymoma.''
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
April 2, 2014 will be considered.
ADDRESSES: Requests for copies of the patent application(s), inquiries,
comments, and other materials relating to the contemplated Start-Up
Exclusive Patent License Agreement should be directed to: Whitney A.
Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337;
Facsimile: (301) 402-0220; Email: hastingw@mail.nih.gov. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the
[[Page 15137]]
World Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: This technology describes fully human
monoclonal antibodies that have been affinity maturated against IGF-I
and IGF-II and display extremely high affinities for IGF-I and IGF-II
in the picoM range. Some of these antibodies potently inhibited signal
transduction mediated by the IGF-1R interaction with IGF-I and IGF-II
and blocked phosphorylation of IGF-IR and the insulin receptor. In
addition, they inhibited migration in the MCF-7 breast cancer cell line
at the picoM range. Therefore, these antibodies could be used to
prevent binding of IGF-I and/or IGF-II to its concomitant receptor
IGFIR, consequently, modulating diseases such as cancer.
The prospective Start-Up Exclusive Patent License Agreement is
being considered under the small business initiative launched on
October 1, 2011 and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR part 404. The prospective Start-Up Exclusive
Patent License Agreement may be granted unless the NIH receives written
evidence and argument, within fifteen (15) days from the date of this
published notice, that establishes that the grant of the contemplated
Start-Up Exclusive Patent License Agreement would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-Up Exclusive Patent License
Agreement. Comments and objections submitted to this notice will not be
made available for public inspection and, to the extent permitted by
law, will not be released under the Freedom of Information Act, 5
U.S.C. 552.
Dated: March 14, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-05867 Filed 3-17-14; 8:45 am]
BILLING CODE 4140-01-P
